Plain-English translation of NCT07611838 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are building a tool using machine learning to predict which people with allergic bronchopulmonary aspergillosis (a fungal lung infection) are at high risk of their disease returning. The tool uses information from your medical records, blood tests, fungal samples, imaging scans, and lung function tests to spot patterns that show who might relapse. This way, doctors can give extra attention to high-risk patients and help prevent their condition from coming back.
Currently, doctors have a hard time knowing which patients will relapse and need closer monitoring or stronger treatment. By identifying patients at highest risk earlier, this treatment approach could help prevent relapses and improve outcomes for people living with this serious fungal lung condition.
You likely qualify if…
You likely don't qualify if…
You would share your existing medical records, blood test results, imaging scans, and lung function test results that were already collected as part of your regular care. Researchers would use this information to develop their prediction tool. You would be followed for one year to track whether your fungal lung condition returns or stays stable. This is an observation study—you won't receive any new medication or invasive procedures as part of the research itself.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China
Sponsor
Qianfoshan Hospital
Enrollment target
~300 participants
Started
January 2021
Primary completion
December 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qian Qi
Shandong First Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.